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Abstract
Background: Noninvasive ventilation (NIV) is a cornerstone for the treatment of acute respiratory failure of
various etiologies. Using NIV is discussed in mild-to-moderate acute respiratory distress syndrome (ARDS)
patients (PaO2/FiO2 > 150). These patients often have comorbidities that increase the risk for bronchoscopy
related complications. The primary outcome of this prospective observational study was to evaluate the
feasibility, safety and contribution in diagnosis and/or modification of the ongoing treatment of fiberoptic
bronchoscopy (FOB) in patients with ARDS treated with NIV.
Methods: ARDS patients treated with NIV and who require FOB as the diagnostic or therapeutic procedure
were included the study. Intensive care ventilators or other dedicated NIV ventilators were used. NIV was
applied via simple oro-nasal mask or full-face mask. Pressure support or inspiratory positive airway pressure
(IPAP), external positive end expiratory pressure (PEEP) or expiratory positive airway pressure (EPAP) levels
were titrated to achieve an expiratory tidal volume of 8 to 10 ml/kg according to ideal body weight, SpO2 > 90 % and
respiratory rate below 25/min.
Results: Twenty eight subjects (mean age 63.3 ± 15.9 years, 15 men, 13 women, PaO2/FiO2 rate 145 ± 50.1 at
admission) were included the study. Overall the procedure was well tolerated with only 5 (17.9 %) patients showing
minor complications. There was no impairment in arterial blood gas and cardiopulmonary parameters after FOB.
PaO2/FiO2 rate increased from 132.2 ± 49.8 to 172.9 ± 63.2 (p = 0.001). No patient was intubated within 2 h after the
bronchoscopy. 10.7, 32.1 and 39.3 % of the patients required invasive mechanical ventilation after 8 h, 24 h and 48 h,
respectively. Bronchoscopy provided diagnosis in 27 (96.4 %) patients. Appropriate treatment was decided according
to the results of the bronchoscopic sampling in 20 (71.4 %) patients.
Conclusion: FOB under NIV could be considered as a feasible tool for diagnosis and guide for treatment of patients
with ARDS treated via NIV in intensive care units. However, FOB-correlated life-treathening complications in severe
hypoxemia should not be forgotten. Furthermore, further controlled studies involving a larger series of homogeneous
ARDS patients undergoing FOB under NIV are needed to confirm these preliminary findings.
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Background
Noninvasive ventilation (NIV) is defined as any form of
ventilatory support applied without endotracheal intub-
ation [1]. Application of NIV is a cornerstone for the
treatment of acute respiratory failure of various etiolo-
gies [2]. It reduces intubation rate in patients with exac-
erbations of chronic obstructive pulmonary disease
(COPD) and acute cardiogenic pulmonary edema [3]
and in immunocompromised patients with hypoxemic
respiratory failure [4, 5]. Using NIV is discussed in mild-
to-moderate acute respiratory distress syndrome (ARDS)
patients (PaO2/FiO2 > 150) [6].
Fiberoptic bronchoscopy (FOB) may be required in
some patients with acute respiratory failure in intensive
care units (ICU), mainly as diagnostic tool or to remove
abundant secretions [7, 8]. As a matter of fact it may
also be applied to determine the cause of diffuse pul-
monary infiltrates (infection, diffuse alveolar
hemorrhage, organizing pneumonia) [9]. Other indica-
tions for FOB in critically ill patients consist of atelec-
tasis, hemoptysis and suspicion of lung neoplasia.
Patients in ICU for acute respiratory failure often have
comorbidities that increase the risk of bronchoscopy
related complications. Feasibility of bronchoscopy dur-
ing NIV in patients with respiratory failure was shown
previously and NIV was found to be superior to con-
ventional oxygen supplementation for preventing gas-
exchange deterioration during FOB [10, 11]. In those
studies, NIV was used to facilitate bronchoscopy and
NIV was not required prior to bronchoscopy. However,
there is limited data on the feasibility and usefulness of
FOB in patients who are already treated with NIV for
acute respiratory failure [12] and in particular there is
not enough evidence for using NIV in patients with
ARDS [6]. Therefore, we aimed to evaluate the feasibil-
ity and safety of FOB in patients with ARDS ventilated
with NIV and its contribution in the diagnosis and/or
modification of the ongoing therapy.
Methods
The patients hospitalized in 8-bed ICU at Ege University
Medical School Department of Chest Diseases were
assessed in terms of ARDS, NIV treatment and FOB
application. The decision both to initiate NIV and to
perform FOB were made by the pulmonologist. This
prospective observational study was approved by the Ege
University Ethical and Research Project Committee
(2010-TIP-088). All study participants or legal represen-
tatives provided written informed consent before the
procedures.
Study population
The study population was obtained from the specified re-
spiratory intensive care unit (January 2010-December 2014).
Inclusion criteria were: 1. ARDS diagnosed by Berlin
criteria or The American-European Consensus Confer-
ence [13, 14], 2. Age ≥ 18 years, 3. Treated with NIV be-
fore the bronchoscopy 4. Requiring FOB with or without
bronchoalveolar lavage (BAL) for diagnostic or thera-
peutic apporach, 5. Informed consent. Exclusion criteria
were: 1. Refusal of NIV, 2. Presence of contraindications
for NIV such as facial deformity, upper gastrointestinal
bleeding, upper airway obstruction, inability to protect
the airway, significantly altered mental status, severe
haemodynamic instability, respiratory or cardiac arrest and
acute coronary syndromes, 3. Tracheostomy or intubation
before admission, 4. Presence of contraindications for bron-
choscopy procedure such as insufficient platelet number
(<70,000 cells/μL) and coagulation disorders, 5. Patients
with NIV use at home prior to ICU admission.
Demographic characteristics, comorbid diseases, pres-
ence of immunosuppression, Acute Physiology and
Chronic Health Evaluation II (APACHE II) score [15]
and radiologic and laboratory findings were recorded for
each patient. Acquired immunodeficiency syndrome,
immunosuppressive medication, organ transplantation,
high dose chemotherapy during the past 60 days,
absolute neutrophil count < 1000/mL were defined as
immunosuppression. Standard microbiological diagnostic
measures before FOB and additional serological studies
were ordered in immunosuppressed patients as indicated.
Heart and respiratory rates, blood pressures and arterial
blood gases were assessed 15 min before and 1 h after the
FOB for this study. These measurements and ventilator
settings were monitored during FOB.
Noninvasive ventilation
All patients were on NIV prior and throughout the
bronchoscopic sampling in the ICU. NIV was applied
via simple oro-nasal mask (AF 531 Oro-nasal mask,
Philips Respironics) or full-face mask (PerforMax Total
face mask, Philips Respironics) (Fig. 1) and the ventilator
settings were adjusted by the pulmonologist. ICU venti-
lator (Servo 900C, Siemens) or dedicated NIV ventilator
(VIVO 40, General Electric) devices were set with the
optimal required FiO2. Pressure support or inspiratory
positive airway pressure (IPAP), external positive end ex-
piratory pressure (PEEP) or expiratory positive airway
pressure (EPAP) levels were titrated to achieve an ex-
piratory tidal volume of 8 to 10 ml/kg according to ideal
body weight, adjusted to maintain SpO2 > 90 % and re-
spiratory rate below 25/min.
Bronchoscopy procedure
Throughout the NIV treatment and bronchoscopy pro-
cedure electrocardiography, intra arterial blood pressure,
pulse oximeter and ventilator parameters were moni-
tored continuously. The ICU bronchoscopy team was
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composed of two well-trained pulmonologists (FB,
MST) and two nurses. All bronchoscopies were per-
formed while patients were in upright position and in
their own beds. 10 % lidocaine spray solution and 2 %
lidocaine solution were used for topical anaesthesia of
nasopharynx and tracheobronchial tree, respectively. A
connector (bronchoscopy elbow, Philips Respironics)
was used between the ventilator tubing and the mask
for the insertion of FOB (Olympus BFU 180F) (Fig. 1).
Fiberoptic bronchoscopy was performed via nasal route.
Short term sedation was administered in some patients
according to their respiratory and hemodynamic situa-
tions. Sedation was started using 2 mg midazolam at
the beginning of the procedure. The patients who did
not achieve stabilisation received repetitive applications
of 1 to 2 mg midazolam. Maximum total dose of mid-
azolam was 5 mg. Patients were supplied with the ne-
cessary FiO2 which provided SpO2 > 90 % during FOB
procedure (one or more of these procedures were per-
formed in same FOB application: BAL, bronchoscopic
brushings and biopsy, aspiration) under NIV. The bron-
choscopic samples were sent to microbiology and path-
ology laboratories. Antimicrobial treatment was started
empirically while the sampling was performed and, later
treatment was adjusted according to microbiological
results.
Outcomes
Primary outcomes were: 1. Safety with the recording of any
complications [such as fever, arrhythmia, hypoxemia (SpO2
< 90 %), hypotension (systolic and diastolic blood pressure
below 90 mmHg and 60 mmHg, respectively), haemorrhage
and pneumothorax]. 2. Contribution of FOB in diagnosis
and/or modification of the ongoing treatment. 3. Require-
ment for endotracheal intubation was specifically observed
within two hours and eight hours after the FOB. Criteria of
two and eight hour limit for endotracheal intubation were
adopted from previous studies [16, 17].
Data analyses
Data management and analysis of all data were con-
ducted via SPSS for Windows 16.0 software (SPSS,
version 16, Chicago). Kolmogorov-Smirnov test was
used to present the distribution of all recorded vari-
ables. Arterial blood gases and haemodynamic param-
eters before and after FOB were compared with
Wilcoxon test. Statistical significance level was set at
p < 0.05.
Fig. 1 a Used connector between the ventilator tubing and the mask for the insertion of FOB, b Oro-nasal mask, c Full-face mask
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Results
Patient characteristics
Twenty eight subjects (mean age 63.3 ± 15.9 years, 15
men, 13 women) were included the study. 20 patients
(71.4 %) had immunosuppression. Patients had
hematologic malignancy, solid-organ tumor, renal
transplantation, long-term corticosteroid treatment
due to interstitial lung disease or connective tissue
disease that caused immunosuppression. The most
common admission diagnosis to ICU was pneumonia
(Table 1). As shown on Table 2, FOB indications
were: suspicion of opportunistic infections in 18 pa-
tients (64.3 %), alveolar hemorrhage in 4 patients
(14.3 %), suspicion of malignancy in 4 patients
(14.3 %), aspiration as therapeutic approach in 4 pa-
tients (14.3 %) and other indications were exacerba-
tion of idiopathic pulmonary fibrosis, drug induced
pulmonary toxicity and pulmonary involvement of
rheumatoid arthritis. Fiberoptic bronchoscopy was
performed with ICU ventilator in 82.1 % of patients
and dedicated NIV ventilators were used for the
remaining patients. PaO2/FiO2 ratio before FOB appli-
cation was calculated as 132.2 ± 49.8. Twenty three
(82.1 %) patients received 100 % FiO2 during FOB to
allow SpO2 levels which must be achieved above 90 %.
Pressure support, IPAP and EPAP/PEEP values during
FOB were 9 (0–18), 20 (8–28) and 8 (5–12) cmH2O,
respectively.
Tolerance and safety of fiberoptic bronchoscopy
The median duration of NIV prior to FOB was 3 h (range
0–72 h). Vasopressor/inotropic agents before the FOB ap-
plication were begun in 4 patients (14.3 %) due to
hemodynamic instability. Thirteen patients (46.4 %) re-
ceived sedation for NIV and/or FOB. Maximum duration
of the bronchoscopy was 20 min and FOB application was
performed only once for each patients. Arterial blood gas
analyses, PaO2/FiO2 rates and cardiorespiratory parame-
ters before and after FOB were shown in Table 3. There
was no impairment in these parameters after bronchos-
copy. PaO2/FiO2 rate increased from 132.2 ± 49.8 to 172.9
± 63.2 after procedure. Pressure support, IPAP, EPAP/
PEEP and FiO2 levels did not change during FOB.
Respiratory and hemodynamic variables were
followed up very closely for the required intubation.
Complications other than endotracheal intubation de-
veloped in 5 (17.9 %) patients within 12 h after FOB.
Fever (n = 2), hypoxemia (n = 1) and hypotension (n =
2) occurred as complication of bronchoscopy. In one
of these patients, hypotension developed within the
first four hours. No other adverse effects were ob-
served such as haemorrhage and pneumothorax.
Endotracheal intubation was not required within
2 h after the bronchoscopy. Intubation was performed
only in three patients (10.7 %) within 8 h. Two of
them had severe coinfection with Cytomegalovirus
and Pneumocystis jiroveci. 32.1 and 39.3 % of the pa-
tients required IMV within 24 h and 48 h, respect-
ively. Due to deterioration of respiratory failure or
septic shock, 6 patients (21.4 %) were intubated after
48 h of the procedure. Five of them had hospital ac-
quired infection in their follow ups.
Clinical usefulness of fiberoptic bronchoscopy
Bronchoscopy contributed to diagnosis of 27 (96.4 %) pa-
tients. Bacteria (n = 2), fungus (n = 18), cytomegalovirus
(n = 12), other viruses (n = 5) and M. tuberculosis (n = 1)
were isolated in 23 (82.1 %) patients as underlying infec-
tious agent. Candida spp. was accepted as cause of
infection for 6 patients, because 3 patients were immuno-
suppressive and we found no other etiologic
opportunistic infection agents in the remaining pa-
tients. Various combinations of the infectious agents
were shown in 12 (42.9 %) patients. Alveolar hemorrhage
was diagnosed in 4 patients and malignancy was reported
as a result of cytologic examination in 2 patients. While
secretions were being removed in 3 patients, atelectasis
was resolved in one patient by FOB. Appropriate
Table 1 Patient characteristics at admission (n = 28)
Age (yrs) 63.3 ± 15.9
Gender (male), n (%) 15 (53.6)




















Immunosuppression, n (%) 20 (71.4)
APACHE II scorea 15.5 (9–27)
PaO2/FiO2 145 ± 50.1
The diagnosis of hospitalisation, n (%)
Pneumonia
Alveoler hemorrhage











Chest X-ray findings, n (%)
Bilateral alveolar infiltrates
Bilateral interstitial infiltrates





Abbreviations: APACHE II acute physiology assessment and chronic health
evaluation II, ARDS acute respiratory distress syndrome
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treatment was arranged in 20 patients (71.4 %) according
to FOB results. Initial empirical treatments were appropri-
ate in the remaining patients.
Discussion
The study demonstrated that bronchoscopy under NIV
is feasible, safe and an effective diagnostic procedure,







Infectious agents Intubation Intubation
time (hour)
1 Pneumonia + Severe Opportunistic infections Infection CMV -
2 Pneumonia + Mild Opportunistic infections Infection Geotrichum capitatum + 24–48
3 Pneumonia - Severe Opportunistic infections Infection Aspergillus spp.,
Respiratory virus
-
4 Pneumonia + Mild Opportunistic infections Infection C. albicans, CMV,
Respiratory virus
-
5 Pneumonia + Moderate Opportunistic infections Infection C. albicans, CMV -
6 Alveoler
hemorrhage
+ Moderate Alveoler hemorrhage Alveoler
hemorrhage
-
7 Respiratory failure - Moderate Aspiration Infection Non-albicans Candida + >48
8 Pneumonia + Severe Alveoler hemorrhage Alveoler
hemorrhage
CMV + 8–24
9 Respiratory failure - Moderate Aspiration Infection CMV, Aspergillus spp.,
C. albicans
+ >48
10 Pneumonia - Moderate Malignancy Infection K. pneumoniae, CMV -
11 Pneumonia - Mild Malignancy Infection C. albicans + 8–24
12 Pneumonia + Moderate Opportunistic infections Infection CMV, PcP + <8
13 Pneumonia - Severe Opportunistic infections Infection CMV, C. albicans -
14 Pneumonia - Severe Aspiration Infection C. albicans + 8–24
15 Alveoler
hemorrhage
+ Moderate Alveolar hemorrhage Infection C. albicans -
16 Respiratory failure + Moderate Opportunistic infections Infection CMV, PcP + <8
17 Pneumonia + Moderate Opportunistic infections Alveoler
hemorrhage
-
18 Respiratory failure + Mild Opportunistic infections Infection C. albicans + 24–48
19 Pneumonia + Moderate Opportunistic infections Malignancy
Infection
P. aeruginosa + 8–24
20 Respiratory failure + Severe Opportunistic infections Infection C. albicans, Respiratory
viruses
-
21 Pneumonia - Moderate Aspiration - + 8–24
22 Alveoler
hemorrhage
+ Severe Alveoler hemorrhage Alveoler
hemorrhage
-
23 Pneumonia + Severe Multiple etiologiesa Infection Acremonium, CMV + <8
24 Pneumonia + Moderate Multiple etiologiesb Infection C. albicans, Respiratory
viruses, CMV
+ >48




26 Pneumonia + Moderate Opportunistic infections Infection C. albicans + 8–24
27 Pneumonia + Severe Multiple etiologiesd Malignancy + >48
28 Pneumonia + Moderate Opportunistic infections Infection M. tuberculosis + >48
Abbrevations: CMV cytomegalovirus, PcP Pneumocystis jiroveci pneumonia
aOpportunistc infections, exacerbation of idiopathic pulmonary fibrosis
bMalignancy, alveoler hemorrhage, opportunistic infections, drug induced pulmonary toxicity
cPulmonary involvement of rheumatoid arthritis, opportunistic infections, drug induced pulmonary toxicity
dOpportunistc infections, malignancy
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therapeutic approach and guide for treatment in ARDS
patients. After the procedure, arterial blood gas values,
PaO2/FiO2 rate, and cardiac parameters did not change
and none of the patients needed intubation within two
hours after bronchoscopy. Fiberoptic bronchoscopy can
be performed safely without major complications in this
group of patients.
Diagnostic or therapeutic bronchoscopy is necessary
for some ICU patients treated for acute respiratory fail-
ure, however it can be associated with various complica-
tions as well as mortality. Because of these risks, FOB
can be challenging in these patients. Bronchoscope
covers 10–15 % of the tracheal lumen and may increase
respiration efforts and decrease PaO2 by 10–20 mmHg
causing respiratory and cardiac complications [18].
Additionally, BAL sampling may cause worsening of
oxygen desaturation [19]. The American Thoracic Soci-
ety recommends avoiding FOB and BAL in patients with
hypoxemia (PaO2 < 75 mmHg or oxygen saturation
<90 % with supplemental oxygen) [20]. Although alter-
native approaches in these patients with higher-risk are
empirical treatments or intubation for FOB, the observa-
tional study and the randomized controlled trials have
shown that NIV may be an alternative to endotracheal
intubation in these critically ill patients who are not pre-
viously ventilated [10, 11, 21].
Early etiological diagnosis in critically ill patients is im-
portant for appropriate treatment. Baumann et al. [12]
showed that BAL during NIV yielded diagnostic infor-
mation in 68 % of the patients with acute respiratory
failure. Diagnostic success of FOB was 59 % in another
study in which oxygen supplementation or NIV applica-
tion was used during the procedure [22]. Our immuno-
suppressed patient ratio was higher than the study
population of Bauman et al. and Cracco et al. (71.4 % vs
53 %, 53 %, respectively). Clouzeau et al. [16] found that
diagnostic or therapeutic information ratio was 75 % in
patients who underwent FOB under NIV. 83.3 % of their
patients were immunocompromise. In our study, diag-
nostic accuracy of FOB in ARDS patients was 96.4 %.
High diagnostic rate in our study can be interpreted with
the fact that we performed sampling with FOB just as
the patients apply to ICU. At the same time, FOB appli-
cation allowed the therapeutic approaches such as aspir-
ation. Furthermore, Agarwal et al. [23] have shown that
NIV-assisted bronchoscopic lung biopsy is another diag-
nostic method in hypoxemic patients with diffuse lung
infiltrates.
Azoulay et al. [24] found that deterioration in respira-
tory status occurred in 44.8 % of patients who had BAL
with oxygen. But only 18.7 % of their patients underwent
BAL with NIV. Chiner et al. [21] showed that there were
no significant differences in arterial blood gas levels in pa-
tients with acute respiratory failure before FOB and 2 h
after FOB. Another study showed a significant improve-
ment in arterial blood gas levels of patients with acute de-
compensated COPD due to community-acquired
pneumonia second hour after FOB with NIV [25]. Secre-
tion aspiration might lead to improvement. In our study,
there were no significant changes in arterial blood gas
analyses and cardiac parameters after FOB. Other compli-
cations such as cardiac arrhythmia, pneumothorax or
hemoptysis did not occur in our study population.
Only three patients (10.7 %) were intubated within 8 h
after FOB (5 h, 7 h and 8 h, respectively). Underlying
diseases of these patients were interstitial lung disease
and lung involvement due to connective tissue disease.
The patients were receiving systemic corticosteroid ther-
apy before admission to hospital and FOB was applied
to diagnose opportunistic infections. Three patients died
within 24 h after the procedure. FOB should not be con-
sidered in these cases, because they had severe under-
lying diseases and infections when they were admitted.
Identified mixt infectious agents had a major effect in
their fast progression. Cytomegalovirus and Pneumocystis
jiroveci in two patients, Acremonium and Cytomegalo-
virus in another patient were shown as opportunistic in-
fectious agents. Fiberoptic bronchoscopy usually causes
alteration in gas exchange. In hypoxemic intubated pa-
tients, PaO2 returns to baseline within 2 h [26]. None of
the patients in the current study needed intubation
within 2 h after FOB. Based on this information, FOB
may not have led to intubation in three patients. Bau-
mann et al. [12] found that 40 patients required NIV
prior to the decision to use FOB. Four of them (10 %)
required IMV within 8 h. Within 48 h, 45 % of their pa-
tients were intubated. In Baumann et al.’s study, mean
baseline PaO2/FiO2 value was 176 ± 54 which is higher
than the values of the current study. In the current study
10.7, 32.1 and 39.3 % of patients required IMV within
8 h, 24 h and 48 h, respectively. Clouzeau et al. [16]
assessed BAL application under NIV in which PaO2/
FiO2 of their patients was 181 ± 50 before FOB. None of
the patients was intubated within 2 h, four of 23 patients
(17.4 %) were required IMV within 24 h after the proced-
ure. Presence of the COPD and immunosuppression were
Table 3 Hemodynamic and arterial blood gas parameters
before and after FOB
Parameters Before FOB After FOB p value
Arterial blood gas
pH 7.45 ± 0.12 7.36 ± 0.14 0.07
PaCO2 (mmHg) 41.3 ± 15.6 41.7 ± 16.1 0.56
PaO2/FiO2 132.2 ± 49.8 172.9 ± 63.2 0.001
Mean arterial pressure (mmHg) 96.7 ± 18.8 94.3 ± 19.6 0.43
Heart rate/min 104.0 ± 20.1 102.1 ± 18.6 0.48
The number in boldface reflects p < 0.05
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shown as risk factors for intubation [22]. Intubation rate
in the current study is acceptable according to presented
rates in the literature. Intubation rate reached to 54 % in
patients with acute respiratory failure who received NIV.
Also, NIV failure ratio was 62 % in moderate and 84 % in
severe ARDS [27]. Cases in the current study were not
intubated due to sudden gas exchanges and hemodynamic
deterioration after bronchoscopy. Severe underlying dis-
eases and infection situations should be taken into consid-
eration for IMV.
The authors of this study aware of the discussions
about using NIV in patients with ARDS. But a recent
study which assessed intubation rate and risk factors of
NIV failure in patients with non-hypercapnic acute hyp-
oxemic respiratory failure showed significant differences
for intubation rate among four groups (non-ARDS, mild
ARDS, moderate ARDS, severe ARDS). However, the
mortality rate was not statistically significant and the
time to intubation had no effect on patient mortality
[27]. In patients with hematologic malignancies and
acute respiratory failure, delayed (after NIV failure) vs.
immediate IMV was associated with increased hospital
mortality which was not statistically significant (65 % vs.
58 %) [28]. Early diagnosis and beginning time of true
treatment in patients with immunosuppression may be
as important as ARDS severity. The authors think that
FOB under NIV treatment due to ARDS may be applied
to patients whose PaO2/FiO2 ratio is close to 100 when
their hemodynamic status is stable and procedure is per-
formed in ICU where all intubation equipment for emer-
gency intubation exist.
This study has some limitations. First, there are no
control groups. Enrolment of a control group was not
possible due to ethical reasons, because treatment with
NIV requires in patients with acute respiratory failure.
In other words, it is believed that intubation is not advis-
able solely for FOB applications. Second, the study
population in the current study was small. Third, the
study population was composed of patients with hypox-
emic and hypercapnic respiratory failure. Fourth, the
data about excluded patients was not given and limited
number arterial blood gas analyses were assessed after
FOB. Fifth, these results were from a single center.
Conclusions
In conclusion, FOB under NIV may be safely and effect-
ively applied for diagnosis and treatment of patients with
ARDS in ICU units that is adequately equipped and
staffed for intubation. There are high risks associated
with intubation during FOB and after procedure. There-
fore, these patients should be closely followed up for
ventilation and for other vital parameters. FOB with
NIV may be considered in patients with ARDS for diag-
nosis and treatment, so intubation and its complications
may be avoided in this patient group. More studies with
large sample sizes are required to make a more thorough
assessment of FOB application under NIV in patients
with ARDS.
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